Melanoma survivors are at increased risk for second primary keratinocyte carcinoma
Huiyan Sun MD
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
Contributed equally.
Search for more papers by this authorYayun Li MD
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Contributed equally.
Search for more papers by this authorFurong Zeng MD
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Search for more papers by this authorYu Meng MD
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Search for more papers by this authorSongtao Du MD
Department of Colorectal Surgical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
Search for more papers by this authorCorresponding Author
Guangtong Deng MD
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Correspondence
Guangtong Deng, md
Department of Dermatology
Xiangya Hospital
Central South University
Changsha
Hunan 410008
China
E-mail: [email protected]
Search for more papers by this authorHuiyan Sun MD
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
Contributed equally.
Search for more papers by this authorYayun Li MD
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Contributed equally.
Search for more papers by this authorFurong Zeng MD
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Search for more papers by this authorYu Meng MD
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Search for more papers by this authorSongtao Du MD
Department of Colorectal Surgical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
Search for more papers by this authorCorresponding Author
Guangtong Deng MD
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Correspondence
Guangtong Deng, md
Department of Dermatology
Xiangya Hospital
Central South University
Changsha
Hunan 410008
China
E-mail: [email protected]
Search for more papers by this authorConflict of interest: None.
Funding source: This work was supported by the National Natural Science Foundation of China (no. 82102803, 82103183), and the fellowship of China postdoctoral Science Foundation (nos. 2020 M682594 and 2021T140748).
Abstract
Background
Recent large cohorts have reported that melanoma survivors are at risk of developing second keratinocyte carcinoma (KC). However, the detailed proportion and risk are still unknown. We aimed to comprehensively analyze the risk of developing keratinocyte carcinoma after primary melanoma.
Methods
We conducted systematic literature research in PubMed, Embase, Web of Science, and Cochrane Library published prior to September 13, 2021. Proportion and standardized incidence ratios (SIR) with its corresponding 95% confidence interval (CI) were pooled for assessing the risk.
Results
A total of 15 studies encompassing 168,286 patients were included in our analysis. The pooled proportions of melanoma survivors that developed a subsequent basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and KC were 4.11% (95% CI, 1.32–6.90), 2.54% (95% CI, 1.78–3.31), and 5.45% (95% CI, 3.06–7.84), respectively. The risks of developing a second BCC, SCC, and KC in melanoma survivors were 5.3-fold (SIR 5.30; 95% CI, 4.87–5.77), 2.6-fold (SIR 2.58; 95% CI, 1.33–5.04), and 6.2-fold (SIR 6.17; 95% CI, 3.66–10.39) increased in comparison with the general population. Both fixed effects and random effects models were applied in conducting meta-analysis and reached a consistent conclusion.
Conclusions
Our results indicated melanoma survivors are at elevated risk of experiencing second primary BCC and SCC, which suggested the significance of surveillance for second primary KC and efforts for prevention in patients with a history of melanoma.
Supporting Information
| Filename | Description |
|---|---|
| IJD16309-sup-0001-FigureS1.epsPS document, 3 MB |
Figure S1 Publication bias by Egger's test and sensitivity analysis for the pooled proportions of second primary BCC (a-b), SCC (c-d), and KC (e-f) in melanoma survivors. BCC, basal cell carcinoma; SCC, squamous cell carcinoma; KC, keratinocyte carcinoma. |
| IJD16309-sup-0002-FigureS2.epsPS document, 2.7 MB |
Figure S2 Publication bias by Egger's test and sensitivity analysis for the pooled SIRs of second primary BCC (a-b), SCC (c-d), and KC (e-f) in melanoma survivors. BCC, basal cell carcinoma; SCC, squamous cell carcinoma; KC, keratinocyte carcinoma; SIR, standardized incidence ratios. |
| IJD16309-sup-0003-TableS1.docxWord 2007 document , 13.4 KB |
Table S1 The detailed search strategy of this meta-analysis. |
| IJD16309-sup-0004-TableS2.docxWord 2007 document , 14.1 KB |
Table S2 Newcastle–Ottawa Scale for risk of bias assessment of studies included in this meta-analysis. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Welch HG, Mazer BL, Adamson AS. The rapid rise in cutaneous melanoma diagnoses. N Engl J Med 2021; 384: 72–79.
- 2Helgadottir H, Isaksson K, Fritz I, et al. Multiple primary melanoma incidence trends over five decades: A Nationwide population-based study. J Natl Cancer Inst 2021; 113: 318–328.
- 3Atkins MB, Curiel-Lewandrowski C, Fisher DE, et al. The state of melanoma: Emergent challenges and opportunities. Clin Cancer Res 2021; 27: 2678–2697.
- 4Robert C, Long GV, Brady B, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol 2020; 38: 3937–3946.
- 5Liu H, Kuang X, Zhang Y, et al. ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 Axis. Cancer Cell 2020; 37: 324–39 e8.
- 6Cortez JL, Vasquez J, Wei ML. The impact of demographics, socioeconomics, and health care access on melanoma outcomes. J Am Acad Dermatol 2021; 84: 1677–1683.
- 7Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019; 69: 363–385.
- 8Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023–1075.
- 9Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.
- 10Spanogle JP, Clarke CA, Aroner S, et al. Risk of second primary malignancies following cutaneous melanoma diagnosis: A population-based study. J Am Acad Dermatol 2010; 62: 757–767.
- 11Kimlin MG, Youlden DR, Brodie AM, et al. Risk of second primary cancer in survivors of in situ melanoma. J Invest Dermatol 2019; 139: 842–847.
- 12Caini S, Boniol M, Botteri E, et al. The risk of developing a second primary cancer in melanoma patients: A comprehensive review of the literature and meta-analysis. J Dermatol Sci 2014; 75: 3–9.
- 13Beroukhim K, Pourang A, Eisen DB. Risk of second primary cutaneous and noncutaneous melanoma after cutaneous melanoma diagnosis: A population-based study. J Am Acad Dermatol 2020; 82: 683–689.
- 14Pastor-Tomas N, Martinez-Franco A, Banuls J, et al. Risk factors for the development of a second melanoma in patients with cutaneous melanoma. J Eur Acad Dermatol Venereol 2020; 34: 2295–2302.
- 15van der Leest RJ, Flohil SC, Arends LR, et al. Risk of subsequent cutaneous malignancy in patients with prior melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2015; 29: 1053–1062.
- 16Lallas A, Apalla Z, Kyrgidis A, et al. Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoring. J Am Acad Dermatol 2020; 82: 398–406.
- 17Albert MR, Weinstock MA. Keratinocyte carcinoma. CA Cancer J Clin 2003; 53: 292–302.
- 18Nehal KS, Bichakjian CK. Update on keratinocyte carcinomas. N Engl J Med 2018; 379: 363–374.
- 19Hwang CY, Chen YJ, Lin MW, et al. Elevated risk of second primary cancer in patients with cutaneous malignant melanoma: a nationwide cohort study in Taiwan. J Dermatol Sci 2010; 60: 167–172.
- 20Bhatia S, Estrada-Batres L, Maryon T, et al. Second primary tumors in patients with cutaneous malignant melanoma. Cancer 1999; 86: 2014–2020.
10.1002/(SICI)1097-0142(19991115)86:10<2014::AID-CNCR19>3.0.CO;2-4 CAS PubMed Web of Science® Google Scholar
- 21Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
- 22Zeng F, Chen B, Zeng J, et al. Preoperative neutrophil-lymphocyte ratio predicts the risk of microvascular invasion in hepatocellular carcinoma: a meta-analysis. Int J Biol Markers 2019; 34: 213–220.
- 23Wassberg C, Thorn M, Yuen J, et al. Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden. Br J Cancer 1996; 73: 255–259.
- 24Levi F, La Vecchia C, Randimbison L, et al. Incidence of invasive cancers following cutaneous malignant melanoma. Int J Cancer 1997; 72: 776–779.
10.1002/(SICI)1097-0215(19970904)72:5<776::AID-IJC12>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 25Cantwell MM, Murray LJ, Catney D, et al. Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. Br J Cancer 2009; 100: 174–177.
- 26Bower MR, Scoggins CR, Martin RC 2nd, et al. Second primary melanomas: incidence and outcome. Am Surg 2010; 76: 675–681.
- 27Manganoni AM, Pavoni L, Farisoglio C, et al. Association between multiple cutaneous melanoma and other primary neoplasms. Clin Exp Dermatol 2012; 37: 857–861.
- 28Toth V, Hatvani Z, Somlai B, et al. Risk of subsequent primary tumor development in melanoma patients. Pathol Oncol Res 2013; 19: 805–810.
- 29Asgari MM, Warton EM, Quesenberry CP, et al. Risk of subsequent cutaneous squamous cell carcinoma in patients with melanoma. J Am Acad Dermatol 2014; 71: 521–528.
- 30Jung GW, Dover DC, Salopek TG. Risk of second primary malignancies following a diagnosis of cutaneous malignant melanoma or nonmelanoma skin cancer in Alberta, Canada from 1979 to 2009. Br J Dermatol 2014; 170: 136–143.
- 31Robsahm TE, Karagas MR, Rees JR, et al. New malignancies after squamous cell carcinoma and melanomas: A population-based study from Norway. BMC Cancer 2014; 14: 210.
- 32Espinosa P, Pfeiffer RM, Garcia-Casado Z, et al. Risk factors for keratinocyte skin cancer in patients diagnosed with melanoma, a large retrospective study. Eur J Cancer 2016; 53: 115–124.
- 33van der Leest RJT, Hollestein LM, Liu L, et al. Risks of different skin tumour combinations after a first melanoma, squamous cell carcinoma and basal cell carcinoma in Dutch population-based cohorts: 1989-2009. J Eur Acad Dermatol Venereol 2018; 32: 382–389.
- 34Chattopadhyay S, Hemminki A, Forsti A, et al. Familial risks and mortality in second primary cancers in melanoma. JNCI Cancer Spectr 2018; 2: pky068.
- 35Kroumpouzos G, Konstadoulakis MM, Cabral H, et al. Risk of basal cell and squamous cell carcinoma in persons with prior cutaneous melanoma. Dermatol Surg 2000; 26: 547–550.
- 36Zheng G, Chattopadhyay S, Sundquist K, et al. Types of second primary cancer influence overall survival in cutaneous melanoma. BMC Cancer 2021; 21: 1123.
- 37Belcher SM, Hausmann EA, Cohen SM, et al. Examining the relationship between multiple primary cancers and psychological distress: A review of current literature. Psychooncology 2017; 26: 2030–2039.
- 38Vakharia PP, Kelm RC, Orrell KA, et al. Risks for noncutaneous second primary malignancy in cutaneous malignant melanoma survivors: An analysis of data from the surveillance, epidemiology, and end results (SEER) program. Int J Dermatol 2020; 59: 463–468.
- 39Deng W, Wang Y, Liu X, et al. Assessment of trends in second primary cancers in patients with metastatic melanoma from 2005 to 2016. JAMA Netw Open 2020; 3: e2028627.
- 40Caini S, Radice D, Tosti G, et al. Risk of second primary malignancies among 1537 melanoma patients and risk of second primary melanoma among 52 354 cancer patients in northern Italy. J Eur Acad Dermatol Venereol 2016; 30: 1491–1496.
- 41Nagarajan P, Asgari MM, Green AC, et al. Keratinocyte carcinomas: Current concepts and future research priorities. Clin Cancer Res 2019; 25: 2379–2391.
- 42Nadhan KS, Chung CL, Buchanan EM, et al. Risk factors for keratinocyte carcinoma skin cancer in nonwhite individuals: A retrospective analysis. J Am Acad Dermatol 2019; 81: 373–378.
- 43Singer S, Tkachenko E, Yeung H, et al. Skin cancer and skin cancer risk behaviors among sexual and gender minority populations: A systematic review. J Am Acad Dermatol 2020; 83: 511–522.
- 44Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst 2013; 105: 350–360.
- 45Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol 2018; 78: 237–247.
- 46Mattei PL, Alora-Palli MB, Kraft S, et al. Cutaneous effects of BRAF inhibitor therapy: A case series. Ann Oncol 2013; 24: 530–537.
- 47Peng L, Wang Y, Hong Y, et al. Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: A meta-analysis. Oncotarget 2017; 8: 83280–83291.
